Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5839419 | 0.78 | FGFR1 (0.40) | FGFR1FGFR4HDAC6KDM4ENPC1 | |
| SCHEMBL28232173 | 0.75 | FGFR1 (0.39) | FGFR1FGFR4HDAC6KDM4EALDH1A1 | |
| SCHEMBL29141665 | 0.75 | ADORA2A (0.41) | FGFR1FGFR4ADORA2BKDM4EALDH1A1 | |
| SCHEMBL6016757 | 0.74 | FGFR1 (0.46) | FGFR1FGFR4ADORA2BHDAC6KDM4E | |
| SCHEMBL29601155 | 0.74 | KDM4E (0.35) | ADORA2BKDM4E | |
| SCHEMBL27773226 | 0.74 | POLB (0.44) | FGFR1FGFR4HDAC6KDM4EALDH1A1 | |
| SCHEMBL30586403 | 0.74 | FGFR1 (0.46) | FGFR1FGFR4ADORA2BHDAC6KDM4E | |
| SCHEMBL29601425 | 0.74 | P2RX7 (0.48) | ADORA2BHDAC6 | |
| SCHEMBL782938 | 0.73 | YTHDC1 (0.53) | FGFR1FGFR4HDAC6 | |
| SCHEMBL16972828 | 0.73 | YTHDC1 (0.47) | FGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3997089-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | University Of Virginia Patent Foundation (US) | 2022-05-18 | — | — | EP | claimed |
| US-20220251085-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-11 | — | — | US | disclosed |
| EP-3997089-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | University Of Virginia Patent Foundation (US) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251085-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | DDB1, HSPBP1, ATIC | FGFR1 4478/4885FGFR4 4455/4885ADORA2B 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.